TXMD Key Statistics, Chart & Performance
The current stock price of TXMD is 1.64 USD. In the past month the price increased by 7.89%. In the past year, price increased by 11.56%.
TXMD Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 49.1 | 1.02T | ||
| JNJ | JOHNSON & JOHNSON | 19.93 | 498.51B | ||
| MRK | MERCK & CO. INC. | 12.04 | 263.24B | ||
| PFE | PFIZER INC | 7.81 | 142.09B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 8.26 | 110.36B | ||
| ZTS | ZOETIS INC | 19.94 | 55.71B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 9.49 | 22.51B | ||
| VTRS | VIATRIS INC | 5.38 | 14.44B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 23.71 | 11.31B | ||
| CORT | CORCEPT THERAPEUTICS INC | 79.77 | 7.38B | ||
| AXSM | AXSOME THERAPEUTICS INC | N/A | 7.50B | ||
| BLTE | BELITE BIO INC - ADR | N/A | 5.61B |
Related stock screener links
About TXMD
Company Profile
TherapeuticsMD, Inc. operates as a pharmaceutical company. The company is headquartered in Boca Raton, Florida and currently employs 1 full-time employees. The company went IPO on 2001-01-31. The company receives royalties on products licensed to pharmaceutical organizations that possess commercial capabilities in the relevant territories. The company granted a license to commercialize IMVEXXY, BIJUVA, and prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brands and assigned its exclusive license to commercialize ANNOVERA to Mayne Pharma. IMVEXXY (estradiol vaginal inserts) pharmaceutical product is for the treatment of moderate-to-severe dyspareunia. BIJUVA pharmaceutical product is a Food and Drug Administration (FDA)-approved bioidentical hormone therapy combination of estradiol and progesterone in a single, oral capsule for the treatment of moderate-to-severe vasomotor symptoms due to menopause in women with a uterus. ANNOVERA pharmaceutical product is a one-year ring-shaped contraceptive vaginal system (CVS).
Company Info
THERAPEUTICSMD INC
951 Yamato Road, Suite 220
Boca Raton FLORIDA 33431 US
CEO: Robert G. Finizio
Employees: 1
Phone: 15619611900
THERAPEUTICSMD INC / TXMD FAQ
What does THERAPEUTICSMD INC do?
TherapeuticsMD, Inc. operates as a pharmaceutical company. The company is headquartered in Boca Raton, Florida and currently employs 1 full-time employees. The company went IPO on 2001-01-31. The company receives royalties on products licensed to pharmaceutical organizations that possess commercial capabilities in the relevant territories. The company granted a license to commercialize IMVEXXY, BIJUVA, and prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brands and assigned its exclusive license to commercialize ANNOVERA to Mayne Pharma. IMVEXXY (estradiol vaginal inserts) pharmaceutical product is for the treatment of moderate-to-severe dyspareunia. BIJUVA pharmaceutical product is a Food and Drug Administration (FDA)-approved bioidentical hormone therapy combination of estradiol and progesterone in a single, oral capsule for the treatment of moderate-to-severe vasomotor symptoms due to menopause in women with a uterus. ANNOVERA pharmaceutical product is a one-year ring-shaped contraceptive vaginal system (CVS).
What is the current price of TXMD stock?
The current stock price of TXMD is 1.64 USD. The price decreased by -2.38% in the last trading session.
Does TXMD stock pay dividends?
TXMD does not pay a dividend.
What is the ChartMill rating of THERAPEUTICSMD INC stock?
TXMD has a ChartMill Technical rating of 8 out of 10 and a ChartMill Fundamental rating of 4 out of 10.
What is the Price/Earnings (PE) ratio of THERAPEUTICSMD INC (TXMD)?
The PE ratio for THERAPEUTICSMD INC (TXMD) is 164. This is based on the reported non-GAAP earnings per share of 0.01 and the current share price of 1.64 USD.
What is the Short Interest ratio of THERAPEUTICSMD INC (TXMD) stock?
The outstanding short interest for THERAPEUTICSMD INC (TXMD) is 0.59% of its float.
TXMD Technical Analysis
ChartMill assigns a technical rating of 8 / 10 to TXMD. When comparing the yearly performance of all stocks, TXMD is one of the better performing stocks in the market, outperforming 90.77% of all stocks.
TXMD Fundamental Analysis
ChartMill assigns a fundamental rating of 4 / 10 to TXMD. TXMD scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
TXMD Financial Highlights
Over the last trailing twelve months TXMD reported a non-GAAP Earnings per Share(EPS) of 0.01. The EPS increased by 102.21% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 10.8% | ||
| ROA | 0.78% | ||
| ROE | 1.1% | ||
| Debt/Equity | 0 |